Real time measurement of heparin concentration during cardiopulmonary bypass

Journal of Cardiovascular Surgery

Volumn 40, Issue 5, 1999, Pages 645-651

  Hashimoto, Kazuhiro ^a,b   Sasaki, T ^a   Hachiya, T ^a   Takakura, H ^a   Onoguchi, K ^a   Nagahori, R ^a   Takeuchi, S ^a  

^a Saitama Cardiovasc and Resp Center   (Japan)

^b Dept of Cardiovascular Surgery   (Japan)

Author keywords

Cardiopulmonary bypass; Heparin; Protamines

Indexed keywords

ANTITHROMBIN III; HEPARIN; PROTAMINE;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; PERFUSION; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ANTITHROMBIN III; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEART DISEASES; HEMATOCRIT; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; INJECTIONS, INTRAVENOUS; MONITORING, INTRAOPERATIVE; PROTAMINES; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 0032729799     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-40.
2. Bull BS, Korpman KA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-84.
3. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thoracic Cardiovasc Surg 1975;69:685-9.
4. Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980;79:97-102.
5. Culliford AT, Gitel SN, Starr N, Thomas ST, Baumann FG, Wessler S et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193:105-11.
6. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;85:174-85.
7. Cohen FJ, Camerlengo LJ, Dearing JP. Activated clotting times and cardiopulmonary bypass I: The effect of hemodilution and hypothermia upon activated clotting time. J Extra-Corporeal Technol 1980;12:139-41.
8. Effeney DJ, Goldstone J, Chin D, Krupski WC, Ellis RJ. Intraoperative anticoagulation in cardiovascular surgery. Surgery 1981;90:1068-74.
9. Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Clinical reports. Variability of the activated coagulation time. Anesth Analg 1988;67:469-72.
10. Jobes DR, Schwartz AJ, Ellison N, Andrews R, Ruffini RA, Ruffini JJ. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981;31:161-6.
11. Pifarre R, Sullivan HJ, Montoya A, Bakhos M, Grieco J, Foy BK et al. Management of blood loss and heparin rebound following cardiopulmonary bypass. Semin Thromb Hemost 1989;15(2):32-40.
12. Hill AG, Groom RC, Marino JA, Munoz R, McGowen JK, Devolder R et al. More precise heparin and protamine management during cardiopulmonary bypass. Proceeding of the American Academy of Cardiovascular Perfusion 1990;2:12-6.
13. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel F et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
14. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiv A, Kater K, Goodnough LT et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. J Thorac Cardiovasc Surg 1995;110:46-54.
15. Frater RWM, Oka Y, Hong Y, Tsubo T, Loubser PG, Masone R. Protamine-induced circulatory changes. J Thorac Cardiovasc Surg 1984;87:687-92.
16. Stocking RK, Brown JW, Winn BA, Jallad MS. Protamine-induced allergic reaction following anticoagulation management. J Extra-Corp Tech 1984;16:37-40.
17. Vertrees RA, Engelman RM, Breyer RH, Johnson J, Auvil J, Rousou JA. Protamine-induced anticoagulation following coronary bypass. Proc Am Acad Cardiovasc Perf 1986;7:94-7.
18. Horrow JC. Heparin reversal of protamine toxicity: Have we come full circle? J Cardiothor Anesth 1990;4:539-42.
19. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation. Ann Thorac Surg 1994;58:799-605.
20. Seegers WH. Antithrombin III. Theory and clinical applications. Am J Clin Pathol 1978;69:367-74.
21. Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:518-27.
22. Young JA, Kisker T, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
23. 2 levels during cardiopulmonary bypass. Circulation 1980;61:808-14.
24. Mammen EF, Koets MH, Washington SC, Work LW, Brown JM, Burdick M et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985;11:281-92.
25. Cardoso PFG, Yamazaki F, Keshavjee S, Schaefers HJ, Hsieh CM, Wang LS et al. A reevaluation of heparin requirements for cardiopulmonary bypass. J Thor Cardiovasc Surg 1991;101:153-60.
26. Murabayashi T, Watanabe N, Hayashi K, Tomioka H, Minami K, Abe H et al. A clinical evaluation of the Hepcon/HMS: A new device of monitoring hemostasis management during cardiopulmonary bypass. Kyobugeka 1997;50:459-62.